Skip to main content
NewslettersWatchlist

Omega Therapeutics Inc(OMGA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.35
Day High2.49
Open:2.39
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Novo Nordisk Stock Crushed the Market Today
PR Newswire
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
PR Newswire
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
PR Newswire
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
PR Newswire
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner
PR Newswire
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines
Business Wire
Cellarity Strengthens Executive Leadership Team
Business Wire
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed
Business Wire
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Business Wire
KSQ Appoints Mahesh Karande to its Board of Directors
PR Newswire
Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
PR Newswire
Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
PR Newswire
Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
PR Newswire
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
PR Newswire
Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer
Business Wire
Cellarity Announces Close of $121 Million Series C Financing
PR Newswire
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
PR Newswire
Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
PR Newswire
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
Business Wire
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior
PR Newswire
Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
PR Newswire
Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
PR Newswire
Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer
PR Newswire
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
PR Newswire
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Business Wire
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer
Business Wire
Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines
Business Wire
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
Business Wire
Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New Medicines
Business Wire
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors
Business Wire
Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform
Business Wire
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship’s Pioneering Medicines to Treat Cystic Fibrosis

Profile

Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.